^
BIOMARKER:

KRAS mutation

i
Other names: KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
Entrez ID:
Related biomarkers:
KRAS mutation
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: A2 - Guideline
KRAS mutation
CRC
cetuximab
Resistant: B - Late Trials
KRAS mutation
CRC
trifluridine/tipiracil
Sensitive: B - Late Trials
KRAS mutation
NSCLC
pembrolizumab
Sensitive: B - Late Trials
KRAS mutation
AML
gilteritinib
Resistant: B - Late Trials
KRAS mutation
NSCLC
abemaciclib
Sensitive: B - Late Trials
KRAS mutation
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive: B - Late Trials
KRAS mutation
NSCLC
gefitinib
Sensitive: B - Late Trials
KRAS mutation
NSCLC
selumetinib
Sensitive: B - Late Trials
KRAS mutation
NSCLC
Immunotherapy
Sensitive: B - Late Trials
KRAS mutation
NSCLC
nivolumab
Sensitive: B - Late Trials
KRAS mutation
CRC
regorafenib
Sensitive: B - Late Trials
KRAS mutation
NSCLC
erlotinib
Resistant: B - Late Trials
KRAS mutation
Ovarian Cancer
binimetinib
Sensitive: B - Late Trials
KRAS mutation
NSCLC
pembrolizumab + abemaciclib
Sensitive: C2 – Inclusion Criteria
KRAS mutation
NSCLC
bevacizumab + PCM-075
Sensitive: C2 – Inclusion Criteria
KRAS mutation
NSCLC
trametinib
Sensitive: C2 – Inclusion Criteria
KRAS mutation
LUAD
trametinib
Sensitive: C2 – Inclusion Criteria
KRAS mutation
NSCLC
afatinib + selumetinib
Sensitive: C2 – Inclusion Criteria
KRAS mutation
CRC
sorafenib
Sensitive: C2 – Inclusion Criteria
KRAS mutation
CRC
bevacizumab
Sensitive: C2 – Inclusion Criteria
KRAS mutation
NSCLC
trametinib + TPX-0005
Sensitive: C2 – Inclusion Criteria
KRAS mutation
NSCLC
VS-6766
Sensitive: C2 – Inclusion Criteria
KRAS mutation
NSCLC
CYT 387
Sensitive: C2 – Inclusion Criteria
KRAS mutation
NSCLC
sunitinib
Sensitive: C2 – Inclusion Criteria
KRAS mutation
Ovarian Cancer
VS-6766 + VS-6063
Sensitive: C2 – Inclusion Criteria
KRAS mutation
CRC
bevacizumab + cetuximab
Sensitive: C2 – Inclusion Criteria
KRAS mutation
CRC
cetuximab + dasatinib
Sensitive: C2 – Inclusion Criteria
KRAS mutation
CRC
palbociclib + binimetinib
Sensitive: C2 – Inclusion Criteria
KRAS mutation
Melanoma
trametinib
Sensitive: C2 – Inclusion Criteria
KRAS mutation
CRC
cetuximab + selumetinib
Sensitive: C2 – Inclusion Criteria
KRAS mutation
Pancreatic Cancer
avelumab
Sensitive: C2 – Inclusion Criteria
KRAS mutation
CRC
bevacizumab + PCM-075
Sensitive: C2 – Inclusion Criteria
KRAS mutation
NSCLC
TVB-2640
Sensitive: C2 – Inclusion Criteria
KRAS mutation
Lung Non-Squamous Non-Small Cell Cancer
binimetinib
Sensitive: C2 – Inclusion Criteria
KRAS mutation
NSCLC
nivolumab + rigosertib
Sensitive: C2 – Inclusion Criteria
KRAS mutation
Pancreatic Ductal Adenocarcinoma
pembrolizumab + trametinib
Sensitive: C2 – Inclusion Criteria
KRAS mutation
Thyroid Gland Carcinoma
trametinib
Sensitive: C2 – Inclusion Criteria
KRAS mutation
Multiple Myeloma
selinexor
Sensitive: C3 – Early Trials
KRAS mutation
Childhood B Acute Lymphoblastic Leukemia
GS-9973
Resistant: C3 – Early Trials
KRAS mutation
NSCLC
BAL3833
Sensitive: C3 – Early Trials
KRAS mutation
CRC
BAL3833
Sensitive: C3 – Early Trials
KRAS mutation
CRC
CYAD-101
Sensitive: C3 – Early Trials
KRAS mutation
AML
venetoclax
Resistant: C3 – Early Trials
KRAS mutation
AML
LY3009120
Sensitive: C3 – Early Trials
KRAS mutation
AML
venetoclax + palbociclib
Sensitive: C3 – Early Trials
KRAS mutation
Pancreatic Adenocarcinoma
trametinib
Sensitive: C3 – Early Trials
KRAS mutation
Gastric Cancer
cetuximab
Resistant: C3 – Early Trials
KRAS mutation
NSCLC
PD-L1 inhibitor
Sensitive: C3 – Early Trials
KRAS mutation
CRC
KPT-8602
Sensitive: C3 – Early Trials
KRAS mutation
CRC
EGFR inhibitor
Resistant: C3 – Early Trials
KRAS mutation
AML
venetoclax + midostaurin
Resistant: C3 – Early Trials
KRAS mutation
AML
venetoclax + gilteritinib
Resistant: C3 – Early Trials
KRAS mutation
AML
venetoclax + sorafenib
Resistant: C3 – Early Trials
KRAS mutation
Multiple Myeloma
venetoclax + cobimetinib
Sensitive: C3 – Early Trials
KRAS mutation
CRC
cobimetinib + SAR442720
Sensitive: C3 – Early Trials
KRAS mutation
NSCLC
EGFR inhibitor
Sensitive: C3 – Early Trials
KRAS mutation
NSCLC
cetuximab + avelumab
Resistant: C3 – Early Trials
KRAS mutation
Ovarian Cancer
VS-6766
Sensitive: C3 – Early Trials
KRAS mutation
Endometrial Cancer
VS-6766
Sensitive: C3 – Early Trials
KRAS mutation
NSCLC
BGB-283
Sensitive: C3 – Early Trials
KRAS mutation
NSCLC
osimertinib
Resistant: C3 – Early Trials
KRAS mutation
Endometrial Cancer
cobimetinib + GDC-0068
Sensitive: C3 – Early Trials
KRAS mutation
Ovarian Cancer
cobimetinib + GDC-0068
Sensitive: C3 – Early Trials
KRAS mutation
Endometrial Cancer
BGB-283
Sensitive: C3 – Early Trials
KRAS mutation
LUAD
gefitinib
Sensitive: C3 – Early Trials
KRAS mutation
LUAD
erlotinib
Sensitive: C3 – Early Trials
KRAS mutation
Colorectal Adenocarcinoma
ceritinib
Resistant: C3 – Early Trials
KRAS mutation
NSCLC
X-396
Resistant: C3 – Early Trials
KRAS mutation
CRC
RGX-202
Sensitive: C3 – Early Trials
KRAS mutation
SCCHN
cetuximab
Resistant: C3 – Early Trials
KRAS mutation
NSCLC
sotorasib
Resistant: C3 – Early Trials
KRAS mutation
Thyroid Gland Anaplastic Carcinoma
atezolizumab + cobimetinib
Sensitive: C3 – Early Trials
KRAS mutation
AML
ivosidenib
Resistant: C3 – Early Trials
KRAS mutation
NSCLC
CH4987655
Sensitive: C3 – Early Trials
KRAS mutation
CRC
panitumumab
Resistant: C3 – Early Trials
KRAS mutation
Oral Cancer
cetuximab
Resistant: C3 – Early Trials
KRAS mutation
CRC
irinotecan + metformin
Sensitive: C3 – Early Trials
KRAS mutation
Multiple Myeloma
MEK inhibitor
Sensitive: C3 – Early Trials
KRAS mutation
Multiple Myeloma
RAD
Sensitive: C3 – Early Trials
KRAS mutation
LUAD
pembrolizumab + INCB024360
Sensitive: C3 – Early Trials
KRAS mutation
Ovarian Cancer
TVB-2640
Sensitive: C3 – Early Trials
KRAS mutation
Breast Cancer
TVB-2640
Sensitive: C3 – Early Trials
KRAS mutation
Solid Tumor
selumetinib
Resistant: C3 – Early Trials
KRAS mutation
Biliary Tract Cancer
toripalimab
Resistant: C3 – Early Trials
KRAS mutation
CRC
pembrolizumab + selinexor
Sensitive: C3 – Early Trials
KRAS mutation
NSCLC
durvalumab
Resistant: C3 – Early Trials
KRAS mutation
LUAD
KRAS inhibitor
Resistant: C3 – Early Trials
KRAS mutation
Juvenile Myelomonocytic Leukemia
decitabine
Sensitive: C4 – Case Studies
KRAS mutation
CRC
SNR1611 + zoledronic acid
Sensitive: C4 – Case Studies
KRAS mutation
CRC
CBC9106
Sensitive: C4 – Case Studies
KRAS mutation
Cholangiocarcinoma
trametinib + pazopanib
Sensitive: C4 – Case Studies